LRRK2 expression is enriched in the striosomal compartment of mouse striatum

Neurobiology of Disease

Volumn 48, Issue 3, 2012, Pages 582-593

  Mandemakers, Wim ^a,b   Snellinx, An ^a,b   O'Neill, Michael J ^c   de Strooper, Bart ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Expression; Knockout; LRRK2; Striosome; Transgenic

Indexed keywords

ARGININE; BIOLOGICAL MARKER; GLYCINE; LEUCINE RICH REPEAT KINASE 2; PROTEIN MOR1; PROTEIN RASGRP1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; ASTROCYTE; BRAIN CORTEX; BRAIN DEVELOPMENT; BRAIN REGION; CELL COMPARTMENTALIZATION; CEREBELLUM; CHOLINERGIC NERVE CELL; CONTROLLED STUDY; CORPUS STRIATUM; EXTRACELLULAR MATRIX; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; MOUSE; NONHUMAN; OLIGODENDROGLIA; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STRIOSOME; SUBSTANTIA NIGRA PARS COMPACTA; THALAMUS; TRANSGENIC MOUSE;

ANIMALS; BLOTTING, WESTERN; CORPUS STRIATUM; IMMUNOHISTOCHEMISTRY; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; NEUROGENESIS; NEURONS; PROTEIN-SERINE-THREONINE KINASES;

EID: 84865560576     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.07.017     Document Type: Article

References (51)

1. Alegre-Abarrategui J., et al. LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum. Mol. Genet. 2009, 18:4022-4034.
2. Alexander G.E., et al. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu. Rev. Neurosci. 1986, 9:357-381.
3. Biskup S., et al. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann. Neurol. 2006, 60:557-569.
4. Cookson M.R. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat. Rev. Neurosci. 2010, 11:791-797.
5. Crittenden J.R., Graybiel A.M. Basal Ganglia disorders associated with imbalances in the striatal striosome and matrix compartments. Front. Neuroanat. 2011, 5:59.
6. Crittenden J.R., et al. Dysregulation of CalDAG-GEFI and CalDAG-GEFII predicts the severity of motor side-effects induced by anti-parkinsonian therapy. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:2892-2896.
7. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
8. Fishell G., van der Kooy D. Pattern formation in the striatum: developmental changes in the distribution of striatonigral neurons. J. Neurosci. 1987, 7:1969-1978.
9. Fujiyama F., et al. Exclusive and common targets of neostriatofugal projections of rat striosome neurons: a single neuron-tracing study using a viral vector. Eur. J. Neurosci. 2011, 33:668-677.
10. Galter D., et al. LRRK2 expression linked to dopamine-innervated areas. Ann. Neurol. 2006, 59:714-719.
11. Gerfen C.R. The neostriatal mosaic. I. Compartmental organization of projections from the striatum to the substantia nigra in the rat. J. Comp. Neurol. 1985, 236:454-476.
12. Gerfen C.R. The neostriatal mosaic: multiple levels of compartmental organization. J. Neural Transm. Suppl. 1992, 36:43-59.
13. Gerfen C.R., Surmeier D.J. Modulation of striatal projection systems by dopamine. Annu. Rev. Neurosci. 2011, 34:441-466.
14. Graybiel A.M. Correspondence between the dopamine islands and striosomes of the mammalian striatum. Neuroscience 1984, 13:1157-1187.
15. Graybiel A.M. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci. 1990, 13:244-254.
16. Graybiel A.M. Habits, rituals, and the evaluative brain. Annu. Rev. Neurosci. 2008, 31:359-387.
17. Graybiel A.M., Ragsdale C.W. Histochemically distinct compartments in the striatum of human, monkeys, and cat demonstrated by acetylthiocholinesterase staining. Proc. Natl. Acad. Sci. U. S. A. 1978, 75:5723-5726.
18. Greggio E., Cookson M.R. Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro 2009, 1.
19. Greggio E., et al. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis. 2006, 23:329-341.
20. Han B.S., et al. Expression of the LRRK2 gene in the midbrain dopaminergic neurons of the substantia nigra. Neurosci. Lett. 2008, 442:190-194.
21. Higashi S., et al. Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain. J. Neurochem. 2007, 100:368-381.
22. Hinkle K.M., et al. LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors. Mol. Neurodegener. 2012, 7:25.
23. Huttner W.B., et al. Synapsin I (protein I), a nerve terminal-specific phosphoprotein. III. Its association with synaptic vesicles studied in a highly purified synaptic vesicle preparation. J. Cell Biol. 1983, 96:1374-1388.
24. Jaleel M., et al. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem. J. 2007, 405:307-317.
25. Jimenez-Castellanos J., Graybiel A.M. Compartmental origins of striatal efferent projections in the cat. Neuroscience 1989, 32:297-321.
26. Levesque M., Parent A. The striatofugal fiber system in primates: a reevaluation of its organization based on single-axon tracing studies. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:11888-11893.
27. Li Y., et al. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat. Neurosci. 2009, 12:826-828.
28. MacLeod D., et al. The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 2006, 52:587-593.
29. Mandemakers W., et al. A cell biological perspective on mitochondrial dysfunction in Parkinson disease and other neurodegenerative diseases. J. Cell Sci. 2007, 120:1707-1716.
30. Melrose H., et al. Anatomical localization of leucine-rich repeat kinase 2 in mouse brain. Neuroscience 2006, 139:791-794.
31. Melrose H.L., et al. A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease. Neuroscience 2007, 147:1047-1058.
32. Moehle M.S., et al. LRRK2 inhibition attenuates microglial inflammatory responses. J. Neurosci. 2012, 32:1602-1611.
33. Moratalla R., et al. Differential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:3859-3863.
34. Nichols R.J., et al. 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochem. J. 2010, 430:393-404.
35. Paxinos F.A. The Mouse Brain in Stereotaxic Coordinates 2007, 3rd edition.
36. Piccoli G., et al. LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool. J. Neurosci. 2011, 31:2225-2237.
37. Prensa L., et al. Dopaminergic innervation of human basal ganglia. J. Chem. Neuroanat. 2000, 20:207-213.
38. Sakaguchi-Nakashima A., et al. LRK-1, a C. elegans PARK8-related kinase, regulates axonal-dendritic polarity of SV proteins. Curr. Biol. 2007, 17:592-598.
39. Sharma S., et al. LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative study. Neuropathol. Appl. Neurobiol. 2011, 37:777-790.
40. Shin N., et al. LRRK2 regulates synaptic vesicle endocytosis. Exp. Cell Res. 2008, 314:2055-2065.
41. Shulman J.M., et al. Parkinson's disease: genetics and pathogenesis. Annu. Rev. Pathol. 2011, 6:193-222.
42. Simon-Sanchez J., et al. LRRK2 is expressed in areas affected by Parkinson's disease in the adult mouse brain. Eur. J. Neurosci. 2006, 23:659-666.
43. Surmeier D.J., et al. Dopamine and synaptic plasticity in dorsal striatal circuits controlling action selection. Curr. Opin. Neurobiol. 2009, 19:621-628.
44. Taymans J.M., et al. Distribution of PINK1 and LRRK2 in rat and mouse brain. J. Neurochem. 2006, 98:951-961.
45. Tepper J.M., Bolam J.P. Functional diversity and specificity of neostriatal interneurons. Curr. Opin. Neurobiol. 2004, 14:685-692.
46. Threlfell S., et al. Striatal dopamine release is triggered by synchronized activity in cholinergic interneurons. Neuron 2012, 75:58-64.
47. Tokuno H., et al. Efferent projections from the striatal patch compartment: anterograde degeneration after selective ablation of neurons expressing mu-opioid receptor in rats. Neurosci. Lett. 2002, 332:5-8.
48. Watabe-Uchida M., et al. Whole-brain mapping of direct inputs to midbrain dopamine neurons. Neuron 2012, 74:858-873.
49. West A.B., et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:16842-16847.
50. Westerlund M., et al. Developmental regulation of leucine-rich repeat kinase 1 and 2 expression in the brain and other rodent and human organs: implications for Parkinson's disease. Neuroscience 2008, 152:429-436.
51. Westerlund M., et al. Lrrk2 and alpha-synuclein are co-regulated in rodent striatum. Mol. Cell. Neurosci. 2008, 39:586-591.